促红细胞生成素在心肌缺血和缺血再灌注损伤中应用及其保护作用机制的研究进展  

Research progress of erythropoietin on the application and its protective mechanism in myocardial ischemia and ischemia/reperfusion

作　　者：常晋瑞[1] 赵妍[1] 曹健[1] 王倩[1] 朱娟霞[1] CHANG Jin-rui;ZHAO Yan;CAO Jian;WANG Qian;ZHU Juan-xia(Insititute of Basic Medicine Science,Xi’an Medical University, Xi’an 710021,Shaanxi Province,China)

机构地区：[1]西安医学院基础医学研究所

出　　处：《中国临床药理学杂志》2019年第15期1695-1698,共4页The Chinese Journal of Clinical Pharmacology

基　　金：国家自然科学基金资助项目(31400984);陕西省高校科协青年人才托举基金资助项目(20160230);西安市未央区科技计划基金资助项目(201845)

摘　　要：急性心肌梗死导致的心力衰竭是世界上最主要的死亡原因。心肌缺血破坏心肌活力,导致心脏功能受损。再灌注是临床治疗心肌缺血的有效疗法,而再灌注损伤仍不容忽视。目前已有许多关于促红细胞生成素治疗心肌缺血或缺血再灌注损伤的研究,但效果仍具有争议。现就促红细胞生成素在心肌缺血与缺血再灌注动物模型及临床心肌梗死患者中的应用及其对心肌损伤保护作用的机制做一综述。Heart failure caused by acute myocardial ischemia is the leading cause of death in the world. Myocardial ischemia destroys myo- cardial vitality,leading to impaired cardiac function. Reperfusion is an effective treatment for clinical treatment of myocardial ischemia till now, but the side effects couldn’t be ignored. There are many studies about the role of erythropoietin on myocardial ischemic and ischemia/reperfu- sion injury,but the data is still controversial. The application of erythro- poietin in animal models and clinical patients with myocardial ischemia and/or ischemia/reperfusion and its protective mechanism against myo- cardial injury are reviewed.

关 键 词：促红细胞生成素 心肌缺血 缺血再灌注 心肌梗死 

分 类 号：R972[医药卫生—药品]